Yurdaydin, CihanWedemeyer, HeinerCaruntu, Florin A.Curescu, Manuela G.Yalcin, KendalAkarca, Ulus S.Gurel, SelimZeuzem, StefanErhardt, AndreasLueth, StefanPapatheodoridis, George V.Port, KerstinKeskin, OnurRadu, Monica N.Celen, Mustafa K.Idilman, RamazanStift, JudithMederacke, IngmarHeidrich, BenjaminManns, Michael P.Dienes, Hans Peter2019-10-272019-10-2720120270-9139https://hdl.handle.net/11454/4649563rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) -- NOV 09-13, 2012 -- Boston, MAeninfo:eu-repo/semantics/closedAccessPegylated-Interferon-a-2a plus Tenofovir or Placebo for the treatment of hepatitis delta: First results of the HIDIT-2 studyConference Object56202A203AWOS:000310955601024Q1